Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

See the rest here:
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

Related Posts